REG - Aptamer Group PLC - Appointment of Chief Financial Officer

AptamerAnnouncement

13/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230213:nRSM6408Pa&default-theme=true

RNS Number : 6408P  Aptamer Group PLC  13 February 2023

13 February 2023

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

Appointment of Chief Financial Officer

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, today announces the
appointment of Rob Quinn as Chief Financial Officer and as an Executive
Director of the Board, effective from 1 March 2023.

 

Rob brings a wealth of both scientific and financial experience with
particular expertise in publicly listed biotechnology and pharmaceutical
companies. From 2019-2021 he was CFO of Silence Therapeutics, an AIM-listed
biotech company developing siRNA oligonucleotide technology to treat disease,
where he oversaw the growth of the company from a $50m to $500m market
capitalisation and a dual listing on Nasdaq. Rob was subsequently CFO at
BenevolentAI until January 2022, an AI-driven drug discovery engine, where he
played a key role in the company's European reverse merger into a SPAC listed
on Euronext Amsterdam. Most recently, Rob was CFO at Pharnext, a biotech
company listed on Euronext Paris.

 

Rob has a BSc in Cell and Molecular Biology from University College Dublin and
a PhD in Biochemistry from the University of Manchester. He is an Associate of
The Institute of Chartered Accountants in England and Wales.

 

Dr Arron Tolley, Chief Executive Officer, commented: "I am very pleased to
welcome Rob to the team at Aptamer as permanent CFO. Rob's background in the
oligonucleotide space and experience as a CFO of AIM listed companies made him
an ideal fit for this role. I look forward to working closely with him as we
look to meet the rapidly expanding demand for antibody alternatives, deliver
the next generation of our Optimer platform, and win global contracts across
the life sciences sector.

 

"It has been a pleasure working with Jenny Cutler, who has served as interim
CFO over the past six months. On behalf of the entire team and Board at
Aptamer, I'd like to express our thanks for her guidance and efforts during an
important period for the business."

 

Rob Quinn, Chief Financial Officer, said: "I am delighted to join Aptamer at
this exciting phase in the Company's development. The range of applications
for the Optimer platform is impressive, and I look forward to working with
Arron and the rest of the team as we look to drive growth, maintain commercial
momentum and further develop the Company's technology."

 

Disclosures pursuant to Schedule 2 paragraph (g) of AIM rules:

 

Full Name: Robert Quinn

Age: 40

Robert Quinn holds no ordinary shares in the Company

 

 Current directorships and/or partnerships  Former directorships and/or partnerships (within the last five years):
 None                                       Stratified Medical Limited

                                            BenevolentAI Energy Limited

                                            Silence Therapeutics Inc

 

 

 

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc

Dr Arron Tolley
                                              +44 (0)
1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Mark Brady / Adam
Dawes
+44 (0) 20 3368 3550

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Cara Murphy
                   +44 (0) 20 3100 2000

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone
            +44 (0) 20 3709 5700

aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

 

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) Group develops custom affinity binders
through its proprietary Optimer® platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global antibody market is currently worth over
$145.0 billion. Optimer binders are engineered to address many of the issues
found with alternative affinity molecules, such as antibodies, and offer new,
innovative solutions to bioprocessing, diagnostic and pharmaceutical
scientists.

Aptamer Group has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions that support
discovery and development across the Life Sciences.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAVBLFFXLLBBBB